Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BIIL 284

Known as: BIIL 284 BS, BIIL-284, BIIL-284 BS 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND A clinical study to investigate the leukotriene B(4) (LTB(4))-receptor antagonist BIIL 284 in cystic fibrosis (CF… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2013
2013
Insufficient oxygen delivery to organs leads to tissue dysfunction and cell death. Reperfusion, although vital to organ survival… Expand
2007
2007
Background: Several clinical and experimental lines of evidence suggest that leucotriene B4 (LTB4), an arachidonic acid… Expand
2007
2007
  • Nature Clinical Practice Rheumatology
  • 2007
  • Corpus ID: 34772172
A multicenter, randomized, double-blind trial has failed to demonstrate efficacy of BIIL 284— a leukotriene B4 (LTB4) receptor… Expand
Highly Cited
2005
Highly Cited
2005
Leukotriene B(4) (LTB(4)), a potent leukocyte chemoattractant derived from the 5-lipoxygenase metabolism of arachidonic acid… Expand
2004
2004
Background: Leukotriene B4 (LTB4) has a key role in the pathophysiology of rheumatoid arthritis (RA). Objective: To investigate… Expand
Highly Cited
2001
Highly Cited
2001
BIIL 284 is a new LTB(4) receptor antagonist. It is a prodrug and has negligible binding to the LTB(4) receptor. However… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3